Metabolic Diseases: Clinical Trials

4,066 trials for Metabolic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2908 completed, 344 terminated, 290 unknown, 202 recruiting. 4066 Phase 3, 523 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34066Completed 2908, Terminated 344, Unknown 290, Recruiting 202, Active not recruiting 118, Withdrawn 108, Not yet recruiting 73, Enrolling by invitation 16, Suspended 7
Phase 2523Completed 333, Unknown 65, Recruiting 34, Terminated 33, Withdrawn 23, Active not recruiting 19, Not yet recruiting 11, Enrolling by invitation 5

Follow Metabolic Diseases: new trials by email Literature Review of Metabolic Diseases trials Research Report on Metabolic Diseases

Trials (filtered) newest first · largest first

All 4,066 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
Semaglutide (Wegovy) weekly injection - Gestational Diabetes Mellitus (GDM), Metabolic Syndrome
Phase 2 / Phase 3Not yet recruitingUniversity of Massachusetts, Worcester2262027-09-012026-09-28
CKM For Safe Use of SGLT2i in Type 1 Diabetes
Sotagliflozin Low Dose, Sotagliflozin High Dose, Dual Continuous Glucose and Ketone Monitor - Type 1 Diabetes (T1D)
Phase 3Not yet recruitingUniversity of California, San Diego522027-04-012026-11-04
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
garetosmab - Fibrodysplasia Ossificans Progressiva, FOP
Phase 3Not yet recruitingRegeneron Pharmaceuticals182027-02-022026-11-12
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
AZD6234, Placebo - Obesity, Overweight
Phase 3Not yet recruitingAstraZeneca3302027-01-042026-11-06
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
NXC-201, Dara-CyBorD - Light Chain (AL) Amyloidosis
Phase 3Not yet recruitingNexcella Inc.2602027-01-012026-07-16
Verapamil In Preclinical Type 1 Diabetes
Verapamil 120 Mg/24 Hours Oral Capsule, Extended Release, Placebo, blood sampling - Type 1 Diabetes
Phase 2 / Phase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris502027-01-012026-10-22
Diabetes Prevention Through Genetics, Familial History and Behavior Change
LEGACY DPP, DPP - Prediabetes, Weight Loss
Phase 2 / Phase 3Not yet recruitingMorehouse School of Medicine4002027-01-012026-10-20
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
Laroprovstat, Rosuvastatin 1, Rosuvastatin 2 - Hypercholesterolemia
Phase 3Not yet recruitingAstraZeneca2042026-12-212026-11-12
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
Linvoseltamab, Daratumumab, Bortezomib - Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
Phase 3Not yet recruitingRegeneron Pharmaceuticals3822026-12-182026-10-28
The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)
Venglustat, Imiglucerase - Gaucher's Disease Type III
Phase 3Not yet recruitingSanofi182026-12-112026-11-10
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis
Phase 2 / Phase 3Not yet recruitingAzafaros B.V.2182026-12-102026-10-21
Efficacy and Safety of Modafinil to Treat Fatigue in People With Mitochondrial Disease.
Modafinil (M), Placebo - Mitochondrial Disease
Phase 3Not yet recruitingKenneth Myers, MD152026-12-012026-10-26
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Semaglutide + TAU, Placebo + TAU - Schizophrenia Disorder, Metabolic Syndrome
Phase 3Not yet recruitingAll India Institute of Medical Sciences, Bhubaneswar6002026-12-012026-08-18
A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia
Ferric Bepectate IV Injection, Ferric Carboxymaltose Injection [Ferinject], Ferric Carboxymaltose Injection [Injectafer®] - Iron Deficiency Anemia (IDA)
Phase 3Not yet recruitingAFT Pharmaceuticals, Ltd.13662026-12-012026-08-20
Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
Tralesinidase alfa (TA) - MPS IIIB
Phase 3Not yet recruitingSpruce Biosciences142026-12-012026-09-21
Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder
Kenetik, magnetic resonance imaging scan, Alcohol bar lab - Alcohol Use Disorder, Ketosis
Phase 2 / Phase 3RecruitingUniversity of Pennsylvania602026-12-012026-10-21
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
Enicepatide, Tirzepatide - Type 2 Diabetes Mellitus
Phase 3Not yet recruitingHoffmann-La Roche9482026-12-012026-10-22
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Eloralintide, Placebo - Obesity, Overweight
Phase 3Not yet recruitingEli Lilly and Company30002026-12-012026-11-03
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Lucerastat - Fabry Disease
Phase 3RecruitingIdorsia Pharmaceuticals Ltd.162026-12-012026-11-03
Alpha-Lipoic Acid Added to Dapagliflozin and Insulin Resistance in Type 2 Diabetes
Alpha-Lipoic Acid (ALA), Placebo - Diabetes Mellitus, Type 2, Insulin Resistance Syndrome
Phase 3Not yet recruitingFayoum University702026-12-012026-11-12

Showing 20 of 4066. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 2 (1435)  ·  Diabetes Mellitus (782)  ·  Diabetes Mellitus, Type 1 (317)  ·  Hypercholesterolemia (275)  ·  Dyslipidemias (202)  ·  Osteoporosis (194)  ·  Insulin Resistance (178)  ·  Hyperlipidemias (165)  ·  Obesity (161)  ·  Hypertension (118)  ·  Metabolic Syndrome (106)  ·  Anemia, Iron-Deficiency (92)  ·  Renal Insufficiency, Chronic (92)  ·  Amyotrophic Lateral Sclerosis (90)  ·  Cardiovascular Diseases (89)

Broader conditions

Nutritional and Metabolic Diseases (4061)  ·  Glucose Metabolism Disorders (2255)  ·  Endocrine System Diseases (2180)  ·  Diabetes Mellitus (1339)  ·  Lipid Metabolism Disorders (728)  ·  Pathological Conditions, Signs and Symptoms (603)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (565)  ·  Genetic Diseases, Inborn (528)  ·  Nervous System Diseases (473)  ·  Metabolism, Inborn Errors (434)  ·  Dyslipidemias (430)  ·  Immune System Diseases (415)  ·  Cardiovascular Diseases (373)  ·  Vascular Diseases (369)

Interventions

Metformin (322)  ·  Insulin Glargine (193)  ·  Sitagliptin Phosphate (133)  ·  Atorvastatin (119)  ·  Ezetimibe (100)  ·  Insulin Aspart (92)  ·  semaglutide (91)  ·  dapagliflozin (89)  ·  Rosuvastatin Calcium (85)  ·  Pioglitazone (83)  ·  glimepiride (82)  ·  Simvastatin (76)  ·  Vildagliptin (76)  ·  Insulin (74)  ·  Liraglutide (71)

Sponsors

Novo Nordisk A/S (234)  ·  AstraZeneca (186)  ·  Sanofi (145)  ·  Eli Lilly and Company (144)  ·  Merck Sharp & Dohme LLC (124)  ·  Takeda (89)  ·  Organon and Co (81)  ·  Novartis Pharmaceuticals (80)  ·  Amgen (71)  ·  Pfizer (55)  ·  Boehringer Ingelheim (53)  ·  Novartis (51)  ·  GlaxoSmithKline (39)  ·  Hoffmann-La Roche (33)  ·  Tanabe Pharma Corporation (24)

Countries

United States (1763)  ·  Canada (755)  ·  Germany (701)  ·  United Kingdom (577)  ·  Spain (565)  ·  France (543)  ·  Italy (509)  ·  Poland (481)  ·  Mexico (411)  ·  Australia (409)  ·  Japan (392)  ·  China (388)  ·  Netherlands (375)  ·  Brazil (348)  ·  South Korea (348)

Results publications

PMID 38770818, PMID 39963952, PMID 40576086, PMID 22236356, PMID 31903692, PMID 32998732, PMID 35044568, PMID 22913891, PMID 33078867, PMID 38682786, PMID 23010561, PMID 25504028, PMID 21518985, PMID 32267058, PMID 38979716, PMID 26580237, PMID 26894924, PMID 27402391, PMID 27777279, PMID 30183102, PMID 34298554, PMID 35472672, PMID 24517339, PMID 31606880, PMID 32306296, PMID 21450987, PMID 21883806, PMID 22193143, PMID 22234149, PMID 22862847, PMID 23130654, PMID 23186975, PMID 24170235, PMID 24786834, PMID 26232910, PMID 27977934, PMID 30615985, PMID 30880443, PMID 31769496, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32501595, PMID 32648108, PMID 33874971, PMID 36542287, PMID 17878242, PMID 18093207, PMID 19245711

NIH funding

2015 (46), 2008 (45), 2009 (40), 2025 (37), 2014 (35), 2023 (35), 2016 (33), 2018 (32), 2005 (30), 2017 (30), 2019 (22), 2004 (7), P30CA015083 (2), R21AA031088 (2), U01DK048489 (2)